Media Center

Latest Press Releases

30th August 2024

Imbria to Present Results from Phase 2 IMPROVE-ISCHEMIA Trial of Ninerafaxstat in Patients with Angina and Chronic Coronary Syndrome at the European Society of Cardiology Congress 2024

8th April 2024

Positive Results for Patients with Non-obstructive Hypertrophic Cardiomyopathy Treated with Ninerafaxstat in the Phase 2 IMPROVE-HCM Trial Presented During a Late-Breaking Clinical Trial Session at ACC.24

25th March 2024

Imbria Pharmaceuticals to Present Results from IMPROVE-HCM Trial of Ninerafaxstat in Late-Breaking Clinical Trial Session at American College of Cardiology Annual Scientific Session & Expo (ACC.24)

12th November 2023

Imbria Reports Positive Topline Results for Investigational New Drug Ninerafaxstat in Patients with Cardiac Ischemia and Chronic Stable Angina

7th November 2023

Imbria Reports Positive Topline Results for Investigational New Drug Ninerafaxstat in Patients with Non-obstructive Hypertrophic Cardiomyopathy

16th August 2023

Imbria Pharmaceuticals Completes Enrollment in the Phase 2 IMPROVE-ISCHEMIA Clinical Trial of Ninerafaxstat in Patients with Stable Angina

Latest Publications and Presentations

31st August 2024

ESC Congress 2024 IMPROVE-ISCHEMIA Presentation

8th April 2024

ACC.24 Late-Breaking IMPROVE-HCM Presentation

8th April 2024

Dr. Maron and Dr. Gibson Discuss Ninerafaxstat and IMPROVE-HCM

You Are About to Leave Imbria Pharmaceuticals

The appearance of external hyperlinks does not constitute endorsement by Imbria Pharmaceuticals of the linked websites, or the information, products or services contained therein.

URL: